{
    "organizations": [],
    "uuid": "d0512ad55fa0334b19e3f4cbf42cb5338fd66e8b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-neurocrine-biosciences-q1-loss-per/brief-neurocrine-biosciences-q1-loss-per-share-0-47-idUSASC09YAC",
    "ord_in_thread": 0,
    "title": "BRIEF-Neurocrine Biosciences Q1 Loss Per Share $0.47",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Neurocrine Biosciences Inc:\n* NEUROCRINE BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.47 * Q1 EARNINGS PER SHARE VIEW $-0.30 — THOMSON REUTERS I/B/E/S\n* ONGOING OPERATING EXPENSES FOR 2018 ARE NOW EXPECTED TO APPROXIMATE $395 TO $420 MILLION\n* QTRLY TOTAL REVENUES $71.1 MILLION * Q1 REVENUE VIEW $63.0 MILLION — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-01T04:20:00.000+03:00",
    "crawled": "2018-05-01T20:22:43.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "neurocrine",
        "bioscience",
        "inc",
        "neurocrine",
        "bioscience",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "ongoing",
        "operating",
        "expense",
        "expected",
        "approximate",
        "million",
        "qtrly",
        "total",
        "revenue",
        "million",
        "q1",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}